ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study)

Background: ALK-tyrosine kinase inhibitors increase ORR and PFS times in ALK-fusion positive NSCLC patients. It is therefore crucial to assess the efficacy of different methods for detecting ALK rearrangement. At present, there are most testing methods approved by cFDA to detect ALK rearrangement in China. However, many issues regarding to the procedure and quality control (QC) data of ALK testing in the routine clinical practice is still to be studied. This study is to evaluate the ALK testing platforms, testing procedures, result interpretation quality control and clinicopathological characteristics of ALK positive patients in the real world for Chinese lung cancer patients, and achieve expert consensus on the clinical practice of ALK testing. Conclusion: NSCLC patients harboring ALK gene translocation have unique clinicopathological characteristics. Some problems will still be encountered in the real world clinical practice of ALK testing, which need to be guided by establishment of expert consensus. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1034

Authors: J. Ying, L. Li, W. Li, Y. Li, Q. Xia, X. Teng, Y. Liu, G. Chen, X. Qiu, W. Wu, Ji, Z. Wang, X. Yan, Y. Han, A. The Ratical Study Group

Conference PaperKirk SmithOctober 1, 2019Lung cancer, Real world data, ALK testing

OA0206 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L)

Previous clinical trials demonstrated that alectinib (ALEC) had a longer time-to-progression than crizotinib (CRZ) in 1st-line settings. Information on long-term overall survival (OS), however, is still limited with a few studies having reported that the sequential strategy of “CRZ followed by other ALK-inhibitor” can provide extended OS. In Japan, ALEC was approved for a 1st-line setting earlier than in other countries.We reviewed the clinical data of ALK-rearranged NSCLC patients who received CRZ or ALEC between May 2012 and Dec 2016. Patients were divided into two groups according to the first-administered ALK inhibitor, the CRZ or ALEC group. In order to evaluate the efficacy of the sequential strategy of “CRZ followed by ALEC”, the combined time to treatment failure (TTF) was calculated in the CRZ group as defined by the sum of the “TTF of CRZ” plus the “TTF of ALEC” if patients were treated with ALEC followed by CRZ. In the ALEC group, the “TTF of ALEC” was calculated. The primar..... READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.415

Authors: S. Watanabe, T. Yamanaka, K. Ito, S. Sakata, H. Daga, T. Kijima, K. Hirano, I. Okamoto, A. Nakamura, T. Kozuki, M. Ishihara, K. Azuma, T. Seto, T. Yokoyama, Y. Oya, H. Kobayashi, K. Nishino, Y. Hattori, K. Nakagawa, N. Yamamoto

Real-World OutcomesKirk SmithOctober 1, 2019alectinib, crizotinib, ALK inhibitor, NSCLC, Real world data, sequential treatment